retina

ILM removal increases ease, safety of subretinal injectionsRemoving a small area of internal limiting membrane at the intended site of a subretinal injection allows the injection to be delivered without penetrating the retina.
ILM peeling with retinal staining aids macular hole closurePeeling of the internal limiting membrane with staining of retinal tissues might help macular hole closure and resolve retinal schisis.
4 pattern recognition skills that are relevant in clinic
4 pattern recognition skills that are relevant in clinicKnowledge of pathologic patterns is necessary in medical retina, especially patterns that are unusual or rare. Pattern recognition skills are essential in medical retina. Lawrence Yannuzzi, MD, highlights four patterns that he believes are relevant in clinical practice and should be recognized–and not missed–by retinal specialists.
New paradigm shift in selecting a steroid course prior to FAc implantAs retinal specialists, we are truly fortunate to live in a time where we have several treatment options for patients with diabetic macular edema (DME). A fluocinolone acetonide (FAc) intravitreal implant 0.19 mg (Iluvien, Alimera Sciences) is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.
Gene therapy trial launched for X-linked retinitis pigmentosaResearchers have injected their first patient with a virus engineered to remodel the gene responsible for X-linked retinitis pigmentosa (XLRP).
How pattern, flicker ERG can impact cataract treatment decisionsRetinal issues can impact cataract surgery outcomes, especially for those with multifocal or other premium lenses. While multifocal lenses may allow the patient to see more clearly across a range of distances, they may also decrease the amount of light that reaches the retina, exacerbating any issues that may already be present.
Investigational wet AMD therapies aim for innovative targetsMany investigational drugs under development for the treatment of neovascular age-related macular degeneration (nvAMD) have advanced into the clinical trial stage, including several that are being evaluated in pivotal trials, said Peter K. Kaiser, MD.
Failed cell therapy study offers positives, raises new questionsPatients with a history of frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of age-related macular degeneration (AMD) may not be the best potential candidates for encapsulated cell technology (ECT).
The case of the blurred disc marginsA 16-year-old female was scheduled for her periodic ophthalmic evaluation to update her spectacle lens prescription. At the visit, she reported a history of migraines, but the remainder of her personal and family medical history was non-contributory. She took no medications and had a history of low hyperopic refractive correction.
Sustained-release corticosteroid implant improves, slows progression of diabetic retinopathySustained intraocular delivery of fluocinolone acetonide (FAc) using the FAc 0.19 mg intravitreal implant (Iluvien, Alimera Sciences) improves and slows progression of diabetic retinopathy (DR), according to findings of post-hoc analyses of data from the pivotal Fluocinolone Acetonide for Diabetic Macular Edema (FAME) trials.